Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.22 AUD | 0.00% | -12.00% | +91.30% |
04-23 | Pharmaust CEO Resigns | MT |
04-10 | PharmAust Obtains Approval to Commence Monepantel Extension Study | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical-Epichem
76.6
%
| 4 | 81.8 % | 3 | 76.6 % | -17.15% |
Corporate & Research
23.4
%
| 1 | 18.2 % | 1 | 23.4 % | +13.86% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
95.2
%
| 2 | 56.8 % | 3 | 95.2 % | +54.75% |
United States
3.6
%
| 0 | 5.9 % | 0 | 3.6 % | -44.72% |
Others
0.7
%
| 0 | 3.1 % | 0 | 0.7 % | -80.48% |
Switzerland
0.6
%
| 1 | 34.1 % | 0 | 0.6 % | -98.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Thurn
CEO | Chief Executive Officer | - | 31/08/23 |
Sam Wright
DFI | Director of Finance/CFO | 46 | 31/08/06 |
Roger Aston
CHM | Chairman | 68 | 11/08/13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Roger Aston
CHM | Chairman | 68 | 11/08/13 |
Sam Wright
DFI | Director of Finance/CFO | 46 | 31/08/06 |
Neville Bassett
BRD | Director/Board Member | - | 01/10/18 |
Thomas Duthy
BRD | Director/Board Member | - | 02-04 |
Director/Board Member | - | 28/10/13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 374,065,597 | 270,740,826 ( 72.38 %) | 0 | 72.38 % |
Company contact information
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+91.30% | 56.85M | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B |
- Stock Market
- Equities
- PAA Stock
- Company PharmAust Limited